"Minimizing the need for topical eyedrops and therefore reducing the risk of noncompliance in my glaucoma patients has become even more important. SLT allows me the comfort of being certain the IOP is being controlled and not dependent on the patient’s degree of compliance."
- I. Paul Singh
*Data available in reference article
SLT is now a proven first-line therapy that is gentle and does not damage tissue, which allows for further treatment such as MIGS, if necessary. SLT can prolong the need for eye drops for up to 3 years according to the LiGHT Trial published by the Lancet (March 2019).
SLT eliminates patient non-compliance by putting control of POAG treatment in the hands of the medical provider. SLT can save patients from the medical costs associated with eye drops when SLT is used as replacement therapy, even after being on medications.
SLT can reduce the amount of eye drops prescribed and in some cases eliminate the need altogether, saving your patients the costs of prescription medications.
* Denotes required fields
LiGHT study | The Lancet. 393.10175 NIHR Biomedical Research Center at Moorfields Hospital, NHS Foundation Trust, London, UK. Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, Anurag Garg, Victoria Vickerstaff, Rachael Hunter, Gareth Ambler, Catey Bunce, Richard Wormald, Neil Nathwani, Keith Barton, Gary Rubin, Marta Buszewicz
Market Scope’s 2018 Global Ophthalmic Laser Market Report.